- Oslo Cancer Cluster - https://oslocancercluster.no -

Curida Takover Secures Norwegian Production

To secure Norwegian pharmaceutical production, Oslo Cancer Cluster- member Curida has completed a takeover of Ås produksjonslab AS.

 

Continued Production at Ås
Curida operate in an international marketplace and here the last line of production of pharmaceuticals is mostly taken care of by specialized operators.

«Ås produksjonslab» is a company rich in tradition, it has nine employees and produces many products for Norwegian pharmacies, while also facilitating production on an assignment order basis.

Curida purchase Ås produksjonslab from The Norwegian Apothecary Society (Apotkerforeningen), a union of Norway’s 900 Pharmacies.

However, the lab will continue their production at Ås also after the takeover. And, with a yearly revenue of 21 million NOK, Leif Rune Skymoen, CEO at Curida, believes the takeover combined with the general growth of the company will help balance the budget the upcoming year.

— We are making these strategic moves because Curida gathered 50 million NOK in December by releasing an equal amount of stocks to Canica and Klavness Marine. Furthermore, Investinor was given an option on 25 million NOK worth of stocks, says Head of the Board of Directors, Per S. Thoresen at Curida. Investinor will decide at the end of January.

Securing Norwegian Expertise
As early as December Thoresen informed that part of the money gathered in the end of the year emissions would be used to buy production facilities.

And CEO Per T. Lund at The Norwegian Apothecary Society is also happy with the takeover. He says in a press release that this will contribute to a strong base of Norwegian pharmaceutical production. Additionally, it secures Norwegian Pharmacies delivery of pharmaceuticals in strong demand.

— We are strengthening Norwegian pharmaceutical production and securing important expertise, Thoresen explaines.

Curida is not only securing Norwegian production, they have also become important for Norwegian war time infrastructure. Late 2017 Curida signed a letter of intent with the Norwegian Armed Forces. They now supply raw materials and are responsible for pharmaceutical manufacturing in situations of emergency preparedness, which means in case of conflict, state of war or general emergency.